BB Biotech Overview

  • Year Founded
  • 1993

Year Founded

  • Status
  • Public

  • Stock Symbol
  • BIOEE

Stock Symbol

  • Investments
  • 83

  • Share Price
  • $69.04
  • (As of Wednesday Closing)

BB Biotech General Information

Description

BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Other Capital Markets/Institutions
Stock Exchange
SWX
Corporate Office
  • Schwertstrasse 6
  • 8200 Schaffhausen
  • Switzerland
+41 052 000 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BB Biotech Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$69.04 $50.56 $69.04 - $69.04 $3.82B 55.1M -$8.00

BB Biotech Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 3,133,204 3,109,258 3,627,667 4,740,065
Revenue 391,860 (184,758) (327,811) (376,874)
Net Income 347,346 (229,839) (374,739) (442,781)
Total Assets 3,134,295 3,139,693 3,293,342 3,986,524
Total Debt 382,032 363,002 391,527 388,360
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BB Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BB Biotech‘s full profile, request access.

Request a free trial

BB Biotech Executive Team (18)

Name Title Board Seat
Maria-Grazia Iten-Alderuccio Director, Investor Relations
Claude Mikkelsen Director of Investor Relations
Silvia Schanz Ph.D Director of Investor Relations
Maurizio Bernasconi Ph.D Deputy Head Investment Management Team
Daniel Koller Ph.D Head Investment Management Team
You’re viewing 5 of 18 executive team members. Get the full list »

BB Biotech Board Members (10)

Name Representing Role Since
00000 00000000 00. The Medicines Company Board Member & Vice Chairman 000 0000
00000 00000000 00. Self Chairman & Board Member 000 0000
00000 000000 Self Board Member 000 0000
0000 0000000 00.0 Self Board Member 000 0000
00000 00000 00.0 Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

BB Biotech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BB Biotech‘s full profile, request access.

Request a free trial

BB Biotech Investments & Acquisitions (83)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Annexon Biosciences 01-Jan-2024 0000 Biotechnology
Biohaven 31-Dec-2023 0000 Drug Discovery
Arvinas 28-Nov-2023 0000 00000 Biotechnology
Molecular Templates 13-Jul-2023 0000 0000 Biotechnology
Immunocore 01-Jan-2023 PIPE Drug Discovery 000000000
You’re viewing 5 of 83 investments and acquisitions. Get the full list »

BB Biotech ESG

Risk Overview

Risk Rating

Updated August, 07, 2023

23.72 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,421

Rank

00.0

Percentile

Diversified Financials

Industry

00 of 962

Rank

00.00

Percentile

Asset Management and Custody Services

Subindustry

00 of 453

Rank

00.00

Percentile

To view BB Biotech’s complete esg history, request access »

BB Biotech Exits (53)

Company Name Exit Date Exit Type Exit Size Status Buyers
Annexon Biosciences 01-Jan-2024 0000 Completed
  • 00 0000000
Biohaven 31-Dec-2023 0000 Completed
  • 00 0000000
Arvinas 28-Nov-2023 0000 00000 Completed
  • 10 buyers
ESSA 01-Jan-2019 0000 000 Completed
  • 2 buyers
WaVe Life Sciences 20-Feb-2018 PIPE 00000 Completed
You’re viewing 5 of 53 exits. Get the full list »

BB Biotech FAQs

  • When was BB Biotech founded?

    BB Biotech was founded in 1993.

  • Where is BB Biotech headquartered?

    BB Biotech is headquartered in Schaffhausen, Switzerland.

  • What industry is BB Biotech in?

    BB Biotech’s primary industry is Other Capital Markets/Institutions.

  • Is BB Biotech a private or public company?

    BB Biotech is a Public company.

  • What is BB Biotech’s stock symbol?

    The ticker symbol for BB Biotech is BIOEE.

  • What is the current stock price of BB Biotech?

    As of 13-Apr-2022 the stock price of BB Biotech is $69.04.

  • What is the current market cap of BB Biotech?

    The current market capitalization of BB Biotech is $3.82B.

  • What is BB Biotech’s current revenue?

    The trailing twelve month revenue for BB Biotech is $392M.

  • What is BB Biotech’s annual earnings per share (EPS)?

    BB Biotech’s EPS for 12 months was -$8.00.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »